Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy


There has been a controversy about the prognostic impact of myeloid antigens (MyAgs) in ALL. The issue has now regained significance since an anti-CD33 monoclonal antibody (mAb) is available for clinical treatment, which is considered for AML as well as for CD33 ALL. We evaluated the prognostic impact of MyAgs in uniformly treated patients. From 9/1996 to… (More)
DOI: 10.1038/sj.leu.2403737

3 Figures and Tables


  • Presentations referencing similar topics